Four pillars of innovation
Our pipeline addresses critical unmet needs across the spectrum of epilepsy and acute hospital care — from preemptive seizure treatment to disease prevention to novel intravenous therapies.
PrevEp006 — Preemptive Seizure Treatment (Intranasal Seletracetam)
Intranasal seletracetam — a next-generation SV2A ligand that is at least 10x higher anticonvulsant potency than levetiracetam (Keppra) — for rapid, preemptive treatment of seizures outside the hospital.
- Intranasal delivery for rapid onset of action
- At least 10x higher anticonvulsant potency than levetiracetam
- First-in-human clinical data published in Annals of Neurology (2026)
PrevEp002 — Epilepsy Prevention After Brain Injury
Rational combination therapies using network pharmacology to prevent the development of epilepsy after traumatic brain injury, stroke, and other brain insults. PrevEp003 — alternative combination (currently paused)
- Combination therapies targeting multiple mechanisms
- Anti-inflammatory, anti-mTOR, and neuroprotective compounds
- Strong preclinical evidence in TBI models
PrevEp004 — Neonatal Seizure Treatment (IV Topiramate)
IV Topiramate for neonatal seizures — addressing the lack of FDA-approved treatments for the most vulnerable patients. Granted Orphan Drug Designation by the FDA.
- FDA Orphan Drug Designation
- IV formulation for NICU administration
- No FDA-approved drugs exist for neonatal seizures
PrevEp005 — First Intravenous Statin Therapy (IV Atorvastatin)
A novel intravenous atorvastatin formulation for hospitalized patients unable to take oral medications. 35–40 million persons take statins daily in the US — acute discontinuation worsens neurologic and cardiac outcomes after stroke and coronary syndromes.
- First practical IV statin replacement — no competitors
- Patent protection through 2039 for novel IV formulations
- 505(b)(2) regulatory pathway — seeking outlicense partner
